Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials

作者：Amber F. Gallanis, Shruthi R. Perati, Stephanie Canady, Monica Epstein, Nancy Moore, Audra Satterwhite, Yvonne Mallory, Diane Ahn, Cassidy Bowden, Silvia Figueiroa, John J. Lee, Andre Luiz De Souza, Sarah J. Shin, Jibran Ahmed, Molly Sullivan, Stacy Joyce, Jonathan M. Hernandez, Alice P. Chen, Christine Alewine, Jeremy L. Davis, Andrew M. Blakely · 发表于：Annals of Surgical Oncology · 年份：2026 · DOI：10.1245/s10434-025-18967-2 · 被引用次数：3 · 研究领域：Intraperitoneal and Appendiceal Malignancies、Gastric Cancer Management and Outcomes、Intestinal and Peritoneal Adhesions

BACKGROUND: The efficacy of locoregional therapy with intraperitoneal (IP) drug delivery plus systemic chemotherapy for peritoneal carcinomatosis is understudied. We investigated progression-free survival (PFS) and overall survival (OS) in patients with peritoneal carcinomatosis from gastric, appendiceal, or small bowel adenocarcinoma who received intravenous (IV) and IP paclitaxel plus capecitabine or nilotinib. METHODS: Two separate single-institution phase II clinical trials evaluating IP and IV paclitaxel therapy plus capecitabine or nilotinib for peritoneal carcinomatosis were analyzed. Enrolled patients with peritoneal-only metastatic gastric cancer received IP and IV paclitaxel plus capecitabine. Participants with peritoneal carcinomatosis from appendiceal, gastric, or small bowel adenocarcinoma received IP and IV paclitaxel plus nilotinib. RESULTS: Twelve patients with a median age of 46 years (range 38-64) received bidirectional paclitaxel plus capecitabine. Median overall PFS and OS was 5.3 months (95% confidence interval [CI] 1.5-13.3) and 12.5 months (95% CI 4.7-14.7), respectively. Seven patients with peritoneal carcinomatosis from appendiceal, gastric, or small bowel adenocarcinoma with a median age 59 years (range 46-69) received bidirectional paclitaxel plus nilotinib. Median PFS and OS was 3.6 months (range 2.6-6.6) and 8.3 months (range 2.8-10.2), respectively, for those receiving bidirectional paclitaxel plus nilotinib. Adverse events (AEs) were common; gra...